Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma

BACKGROUND: Current therapies for metastatic melanoma are targeted either at cancer mutations driving growth (e.g., vemurafenib) or immune-based therapies (e.g., ipilimumab). Tumour progression also requires angiogenesis, which is regulated by VEGF-A, itself alternatively spliced to form two familie...

Descripción completa

Detalles Bibliográficos
Autores principales: Gammons, M V, Lucas, R, Dean, R, Coupland, S E, Oltean, S, Bates, D O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119992/
https://www.ncbi.nlm.nih.gov/pubmed/25010863
http://dx.doi.org/10.1038/bjc.2014.342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119992/
https://www.ncbi.nlm.nih.gov/pubmed/25010863
http://dx.doi.org/10.1038/bjc.2014.342

Ejemplares similares